Clinical Trials Logo

Filter by:
NCT ID: NCT03164070 Enrolling by invitation - Osteoarthritis Clinical Trials

Study of the Laboratory-based Evaluation of the Degrees of Activity of Osteoarthritis

Start date: July 1, 2016
Phase: N/A
Study type: Observational

This study evaluates laboratory-based method to estimate the degrees of activity of medium and large joint osteoarthritis.

NCT ID: NCT03164044 Enrolling by invitation - Drug Allergy Clinical Trials

Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Start date: January 3, 2017
Phase: N/A
Study type: Observational

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

NCT ID: NCT03114631 Enrolling by invitation - Clinical trials for Pancreatic Neoplasms

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Start date: January 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer

NCT ID: NCT03072576 Recruiting - Clinical trials for Tuberculosis, Pulmonary

Accuracy and Feasibility of Xpert Ultra

Start date: March 2016
Phase: N/A
Study type: Observational

Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.

NCT ID: NCT03062644 Recruiting - Acute Pain Clinical Trials

Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.

Start date: April 5, 2017
Phase: Phase 3
Study type: Interventional

The MR308-3502 study is a multicenter double-blind, randomised, placebo- and active comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after TAH or STAH (total or subtotal abdominal hysterectomy).

NCT ID: NCT03061812 Recruiting - Clinical trials for Small Cell Lung Cancer

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Start date: April 10, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this randomized, open-label, 2-arm, Phase 3 study is to assess the assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic Small Cell Lung Cancer (SCLC) with high levels of delta-like protein 3 (DLL3) and who have first disease progression during or following front-line platinum-based chemotherapy.

NCT ID: NCT03045302 Terminated - Acromegaly Clinical Trials

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Start date: January 26, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.

NCT ID: NCT03033511 Recruiting - Clinical trials for Small Cell Lung Cancer (SCLC)

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Start date: February 7, 2017
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

NCT ID: NCT03031470 Active, not recruiting - Clinical trials for Early Allograft Dysfunction

Efficacy and Safety Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Orthotopic Liver Transplantation Patients

Start date: March 2015
Phase: Phase 2
Study type: Interventional

Liver transplantation is currently the treatment of choice for end-stage liver cirrhosis of different origin, as well as for a number of inborn metabolism disorders and liver tumors. The need to perform a liver transplantation is high and amounts to 10 - 20 patients per 1 million population per year. Experimental and clinical evidence demonstrate the harmful short and long-term effects of ischemia-reperfusion injury (IRI) of the donor organ on the outcome of the intervention performed. Severe manifestations of IRI of the liver transplant (LT) is one of the main reasons for the increased length of hospitalization, the high cost of treating patients during the post- surgery period, the development of persistent early allograft dysfunction or loss, frequent crises of acute rejection, acute renal and multiple organ failure, and mortality of the operated patients. This pilot clinical study is designed to evaluate the efficacy and safety of Reparixin, which is a new, potent and specific inhibitor of chemokine CXCL8 (Interleukin-8), as an agent to prevent early allograft dysfunction caused by ischemia-reperfusion injury in patients undergoing orthotopic liver transplantation.

NCT ID: NCT03021499 Recruiting - Lupus Nephritis Clinical Trials

Aurinia Renal Response in Active Lupus With Voclosporin

Start date: May 17, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.